SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. announced today that Dr. Douglas Taylor has joined the Science Advisory Board of Exosome Sciences, Inc. (ESI). Dr. Taylor is credited with the discovery of tumor-secreted exosomes and is a leading published author on the topic. ESI, a wholly owned subsidiary of Aethlon Medical, was recently formed to leverage the discovery that the Hemopurifier(R), a medical device being advanced as an adjunct therapy for Hepatitis-C (HCV) and other viral pathogens, is capable of capturing exosomes secreted by solid tumors, lymphomas, and leukemia to suppress the immune response in cancer patients. The targeted removal of circulating exosomes to inhibit cancer related immune suppression could increase patient responsiveness to both immunotherapy and chemotherapy.
“We are honored to have Dr. Taylor become the first member of our ESI science advisory board,” stated Aethlon Chairman and Chief Executive Officer, Jim Joyce. “As we assemble of team of thought leaders in the emerging exosome field, Dr. Taylor will provide important guidance specific to the treatment and diagnoses of ovarian cancer,” concluded Joyce.
About Aethlon Medical
Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier(R) represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier(R) seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.
CONTACT: Jon Cunningham of RedChip Companies, Inc., 1-800-733-2447, ext.
107, Jon@redchip.com; or Jim Joyce, Chairman, CEO, +1-858-459-7800, ext.
301, jj@aethlonmedical.com, or Jim Frakes, Senior VP Finance,
+1-858.459.7800, ext. 300, jfrakes@aethlonmedical.com, both of Aethlon
Medical
Web site: http://www.aethlonmedical.com/
